recent
advanc
synthet
biolog
open
possibl
fine
engin
viral
genom
goal
understand
prevent
viral
diseas
vesicular
stomat
viru
vsv
one
promis
virus
engin
vaccin
oncolyt
therapi
genom
abl
accept
larg
foreign
sequenc
figur
vsv
also
remain
viabl
pseudotyp
viru
envelop
viru
express
foreign
glycoprotein
place
nativ
surfac
protein
broad
tissu
tropism
allow
mani
differ
rout
administr
nasal
spray
intramuscular
inject
vsv
reliabl
grown
high
titer
cell
type
approv
vaccin
product
final
neglig
preexist
immun
vector
exist
gener
popul
protect
viral
infect
vsvvector
vaccin
explor
strategi
protect
mani
emerg
viral
infect
exhibit
except
safeti
efficaci
particular
interest
studi
vsv
express
antigen
highli
pathogen
avian
influenza
induc
steril
immun
heterolog
challeng
mice
experi
imposs
detect
challeng
viru
lung
day
postchalleng
one
studi
vaccin
challeng
macaqu
immunocompromis
simianhuman
immunodefici
viru
shiv
infect
vaccin
well
toler
protect
vaccin
subject
lethal
zair
ebola
viru
zebov
challeng
unvaccin
anim
succumb
day
postchalleng
sever
immunocompromis
vaccin
subject
succumb
zebov
challeng
demonstr
safeti
efficaci
potenti
vsv
live
viru
vaccin
would
otherwis
contraind
although
viral
vector
tradit
util
vaccin
bacteri
agent
potenti
protect
intracellular
bacteria
signific
level
protect
report
challeng
mycobacterium
tuberculosi
mice
week
postvaccin
protect
coincid
elev
shortliv
cell
interferon
ifn
gproduc
cell
follow
intramuscular
inject
even
promis
recombin
vsv
express
secret
form
virul
factor
protein
yersinia
pesti
lcrv
induc
high
level
lcrvspecif
antibodi
protect
mice
challeng
ld
protect
cancer
cell
vsv
known
exquisit
sensit
ifn
mani
cancer
cell
unlik
normal
cell
defici
ifn
respons
therefor
possibl
vsv
kill
tumor
cell
leav
healthi
tissu
tumor
margin
unharm
vsv
highli
immunogen
therefor
detect
neutral
immun
system
tumor
suffici
destroy
introduc
antiinflammatori
glycoprotein
equin
herpesviru
vsv
genom
help
viru
replic
effect
rat
model
hepatocellular
carcinoma
result
signific
increas
area
necrot
cell
within
tumor
also
increas
surviv
anim
safeti
vsv
demonstr
immunocompromis
macaqu
neurovirul
observ
vsv
infect
sourc
concern
howev
research
identifi
mutat
eras
neurolog
sign
surprisingli
also
demonstr
replicationdefici
vector
may
potent
vaccin
replicationcompet
one
observ
address
mani
safeti
issu
relat
use
replic
virus
signific
mileston
start
first
clinic
trial
vaccin
deriv
vsv
two
clinic
trial
recruit
healthi
hivfre
volunt
examin
safeti
potenti
hiv
vaccin
phase
studi
use
either
vsv
express
hiv
gag
protein
primari
vaccin
clinicaltrialsgov
identifi
vsvhiv
gag
booster
primari
vaccin
dna
express
hiv
gag
adjuv
clinicaltrialsgov
identifi
success
trial
dramat
increas
viabil
vsv
deriv
clinic
applic
light
promis
success
wide
varieti
laboratori
studi
seem
though
vsv
becom
chassi
choic
engin
therapeut
virus
target
broad
rang
diseas
genom
small
enough
manipul
bacteri
plasmid
structur
simpl
enough
model
use
comput
assist
design
softwar
applic
synthet
biolog
instanc
genocad
use
gener
logic
represent
therapeut
virus
review
letter
figur
coalesc
progress
synthet
biolog
similarli
sever
acut
respiratori
syndrom
sar
vaccin
design
replac
vsv
g
protein
sar
spike
protein
c
avian
influenza
vaccin
reli
insert
sequenc
code
antigen
immedi
next
leader
sequenc
interestingli
booster
vaccin
carri
differ
variant
vsv
g
protein
escap
antivsv
immun
respons
acquir
primari
immun
tuberculosi
vaccin
reli
insert
antigen
g
l
e
yersinia
pesti
vaccin
structur
compar
avian
influenza
vaccin
f
final
antiinflammatori
oncolyt
vsv
larg
insert
g
l
insert
includ
antiinflammatori
glycoprotein
report
gene
luc
separ
intern
ribosom
entri
site
ire
g
logic
map
gener
use
genocad
trend
biotechnolog
octob
vol
